From GlobeNewswire: 2024-05-08 08:00:00

Indaptus Therapeutics, a biotechnology company, shared financial results for the first quarter of 2024. They continue to progress in their clinical development, presenting positive results at key oncology conferences. Research and development expenses decreased by 15%, with cash and equivalents at $9.7 million. Decoy20 has shown potential in treating cancer and viral infections.

Key highlights include presenting their Decoy20 product at important oncology conferences and gaining a patent to expand their intellectual property portfolio. R&D expenses decreased by 15% compared to the previous year. Operating loss per share improved from $0.51 to $0.45 from 2023 to 2024. Cash and cash equivalents as of March 31, 2024, were $9.7 million, supporting operations until the third quarter of 2024.

Decoy20, a product from Indaptus, has shown promise in activating immune responses against tumors and infections. It employs a multi-targeted immune system activation approach, exhibiting single-agent activity against various cancers and viral infections in pre-clinical models. Decoy20 has the potential to create immunological memory and shift tumors from “cold” to “hot” inflammation signature.



Read more at GlobeNewswire:: Indaptus Therapeutics Reports First Quarter 2024 Financial